ruxolitinib,rusfertide,acalabrutinib,hydroxyurea
astrazeneca,protagonist therapeutics,incyte,novartis
[' aca ', 'rusfertide', 'hydroxyurea', 'rux,(-crux),(-trux),(-deruxtecan)', 'protagonist ']
we are excited to have our phase 3 verify study design featured in ash news today. for more information about the verify study of rusfertide in #polycythemiavera (pv), visit #ash22 
Discovering and developing novel therapies through our proprietary technology platform. #biotech #lifesciences #innovation